Menu
No results found.
Weekly Share Price & Valuation Overview
Dong-A Socio Holdings Co., Ltd.
Dong-A Socio Holdings Co., Ltd., together with its subsidiaries, engages in the pharmaceutical business in South Korea. It operates through Holding Company; Over-the-Counter Drugs and Quai-Drugs; Biosimilars and Consignment Medicines; Logistics; Packaging Solutions; and Others segments. The company develops DA-8010 in Phase 3 clinical trial to treat overactive bladder; DMB-3115, a biosimilar of Stelara in Phase 3 clinical trial; DA-1241 in Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis; DA-1726 in Phase 1 clinical trial to treat obesity; and STP0404 for the treatment of AIDS. It also provides medical devices and equipment; healthcare solutions to customers in Bacchus, over-the-counter, consumer healthcare, and cosmetics; health functional food; contract development and manufacturing organization for biosimilar and pharmaceutical products, and oligonucleotide therapeutics; functional sports drinks under the POCARI SWEAT brand; logistics and fulfillment services; glass bottles, PET bottles, aluminum and plastic caps, and paper packaging boxes; mineral and carbonated water, and mixed drinks; and IT and construction services. In addition, the company is involved in engineering; cargo, courier, and automobile transport arrangement; transportation warehousing and leasing; real estate development; agricultural product distribution; management consulting; business management; and architectural, electric work, fire protection, and housing contracting services. Dong-A Socio Holdings Co., Ltd. was founded in 1932 and is headquartered in Seoul, South Korea.
- Quick ratio <0.8 — tight near-term liquidity without inventory.
- Debt/EBITDA >4 — elevated leverage vs earnings capacity.
- Market Cap Total equity value of the company (share price × shares outstanding).
- KRW 710.14B
- Enterprise Value Operating value: market cap + total debt − cash.
- KRW 1.33T
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- KRW 1.36T
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- KRW 418.62B
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- KRW 179.90B
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- KRW 210.71K
- Dividend Yield Annual dividend ÷ share price. Reconciled using dividend per share when available.
- 1.54%
- Shares Outstanding
- 6.44M
- Float Shares
- 2.84M
- Implied Shares Outstanding
- 6.52M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
6.20%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
13.26%
- Gross Margin (TTM) Reconciled Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
30.86%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
5.02%
- ROA Return on assets: net income ÷ total assets.
-
2.69%
- ROE Return on equity: net income ÷ shareholder equity.
-
6.45%
- Revenue Growth Year-over-year revenue growth.
-
7.70%
- Earnings Growth (YoY) Year-over-year earnings growth.
-
1.28%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
1.28%
- Quick Ratio Liquid current assets ÷ current liabilities (ex-inventory).
- 0.41
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.69
- Total Cash Cash and equivalents.
- KRW 142.02B
- Total Debt Short + long-term interest-bearing debt.
- KRW 746.78B
- Net Debt Total debt − cash (negative = net cash).
- KRW 604.76B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 4.15
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- KRW 104.25B
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- KRW 71.26B
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
7.68%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
5.25%
- Cash Conversion (OpCF/EBITDA)
- 0.58
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.